Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.43 |
| ▸ | CSF1R | P07333 | 3/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.43 |
| ▸ | KIT | P10721 | 3/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.43 |
| ▸ | PLK4 | O00444 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | PAK4 | O96013 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | FLT1 | P17948 | 2/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.43 |
| ▸ | TYK2 | P29597 | 2/20 | 0.43 |
| ▸ | AXL | P30530 | 2/20 | 0.43 |
| ▸ | FLT4 | P35916 | 2/20 | 0.43 |
| ▸ | BLK | P51451 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31576756 | 0.96 | KDR (0.58) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL30786232 | 0.93 | KDR (0.66) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL31576764 | 0.92 | KDR (0.59) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL31576735 | 0.87 | KDR (0.58) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL31576781 | 0.85 | KDR (0.54) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL30786230 | 0.84 | KDR (0.70) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL31576744 | 0.84 | KDR (0.60) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL31475180 | 0.84 | KDR (0.52) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL30786236 | 0.83 | KDR (0.37) | KDRBMPR1BDRD4 | |
| SCHEMBL30786274 | 0.82 | KDR (0.59) | KDRFGFR1CSF1RPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049071-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | BEYANG THERAPEUTICS CO LTD (CN) | 2026-02-19 | — | — | US | disclosed |
| EP-4556466-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | Beyang Therapeutics Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049071-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | KDR, FLT1, ERBB2 | KDR 1/4885FGFR1 70/4885CSF1R 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.